Acute respiratory distress syndrome following cardiovascular surgery

Abstract

Purpose of review This review gives an update on current treatment options and novel concepts on the prevention and treatment of the acute respiratory distress syndrome (ARDS) in cardiovascular surgery patients. Recent findings The only proven beneficial therapeutic options in ARDS are those that help to prevent further ventilator-induced lung injury, such as prone position, use of lung-protective ventilation strategies, and extracorporeal membrane oxygenation. In the future also new approaches like mesenchymal cell therapy, activation of hypoxia-elicited transcription factors or targeting of purinergic signaling may be successful outside the experimental setting. Owing to the so far limited treatment options, it is of great importance to determine patients at risk for developing ARDS already perioperatively. In this context, serum biomarkers and lung injury prediction scores could be useful. Summary Preventing ARDS as a severe complication in the cardiovascular surgery setting may help to reduce morbidity and mortality. As cardiovascular surgery patients are of greater risk to develop ARDS, preventive interventions should be implemented early on. Especially, use of low tidal volumes, avoiding of fluid overload and restrictive blood transfusion regimes may help to prevent ARDS.

Tempering Macrophage Plasticity for Controlling SARS-CoV-2 Infection for Managing COVID-19 Disease

“…Both MSC and macrophages secrete various factors (Boxman et al, 1996;Broughton et al, 2012) that are involved in wound healing. On account of the regenerative potential of macrophages (Chamoto et al, 2012;Hoegl et al, 2016) and their close association with mesenchymal stem cells (Spiller and Koh, 2017;Myneni et al, 2019), these cells can potentially be utilized in a palliative approach (Granata et al, 2010;Almatroodi et al, 2014) for the accelerated recovery of patients. This warrants the use of macrophages and MSC as whole-cell infusions or their products as palliative components for enhancing the recovery of COVID-19 patients after therapeutic interventions.…”

Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity

“…Successful therapy also requires vasculature normalization and homeostasis for normal physiological status. On the basis of regenerative potential of M2 or TAM macrophages these cells can potentially be targeting or enriched as palliative agent (93,94). Although AAM resembles to TAM and secretes various growth factors which (95,96) are sufficient to resolve acute/chronic inflammatory response which in manifested during/post therapy.…”

Macrophages directed approaches are paramount for effective cancer immunotherapies

“…This could be achieved by both subsiding inflammatory response and / or inducing cellular proliferation for replenishing tissue mass which is normally lost during various therapeutic regimens. MSC -based regenerative therapies have been introduced recently which function on their ability to differentiate into different mesenchymal lineages and to function as immunomodulatory / suppressive, angiogenic, antiapoptotic, and proliferative agents [104,105]. Like TAM, MSC also secrete various factors which are involved in wound healing (VEGF, HGF etc.)…”